Astellas hit by fatal event in ASPIRO clinical trial of AT132 in XLMTM
Astellas Pharma said that a participant in the ASPIRO clinical trial of AT132, who had developed a serious adverse event earlier this month, has passed away. The Japanese pharma company said that the cause of death is yet to be determined. The ASPIRO clinical trial is being held in patients with X-linked Myotubular Myopathy (XLMTM), which is […]